Navigation Links
CyberKnife System Achieves 38 Percent Growth in Extracranial Treatments During Fiscal Year 2008
Date:10/24/2008

Full Body Radiosurgery Expands Treatment Options for Patients with Lung,

Prostate, Liver and Pancreatic Cancer

SUNNYVALE, Calif., Oct. 24 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that treatments of extracranial tumors using the CyberKnife(R) Robotic Radiosurgery System increased by 38 percent worldwide during the fiscal year ending June 30, 2008. Specifically, during this time, prostate treatment grew approximately 95 percent worldwide, while lung, liver and pancreas treatments experienced double-digit growth.

The ability of the CyberKnife System to non-invasively target tumors throughout the body with sub-millimeter accuracy is dramatically altering how the medical community and patients view radiosurgery. Designed originally for intracranial use, radiosurgery has long been an alternative to brain surgery. Building on this well established concept, Accuray extended the benefits of radiosurgery to other types of tumors, when the CyberKnife System was cleared in 2001 by the U.S. Food and Drug Administration as the first -- and only -- dedicated radiosurgery system to treat tumors anywhere in the body.

"The CyberKnife System allows us to treat a wide variety of cancer patients -- from those who want to avoid the risks and long recovery time associated with surgery to those who have no other options," said Irving D. Kaplan, M.D., assistant professor, Department of Radiation Oncology at Harvard Medical School and radiation oncologist at Beth Israel Deaconess Medical Center in Boston, Mass. "Because it delivers high doses of radiation with such accuracy, the CyberKnife System effectively targets tumors while shortening tr
'/>"/>

SOURCE Accuray Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. First CyberKnife System Purchased in Latin America
2. Oklahoma CyberKnife Center Cuts Treatment Time in Half With Next Generation CyberKnife Technology
3. St. Lukes Episcopal Hospital to Add CyberKnife System to Treatment Offerings
4. First CyberKnife System Sold in Switzerland
5. CyberKnife Prostate Cancer Planning Study Published in Leading Radiation Oncology Journal
6. CyberKnife Radiosurgery Used to Treat Lung Tumors at 90 Percent of Centers Worldwide
7. CyberKnife Users Meeting Highlights Major Clinical Data Milestones and Emerging Trends
8. Isis Ibis Biosciences Subsidiary Highlights the Power of the Ibis T5000 Pathogen Identification and Characterization System at the ICAAC/IDSA Meeting
9. LI-COR Biosciences and Euthanex Corporation Provide Anesthesia System for Small Animal Imaging
10. Laboratory Pumping Systems to Reach $3.1 Billion by 2012, According to New Report by Global Industry Analysts, Inc.
11. The MaxCyte STX Scalable Transfection System to be Launched at the SBS Symposium on Cell-Based Assays
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... August 27, 2014 Budding Biomedical ... University School participated in the Scientific ... Reserve University’s School of Medicine . ... an unparalleled professional experience in the sciences and ... Medicine faculty and students for both academic and ...
(Date:8/26/2014)... The 20 ambassadors representing the ALS Therapy Development ... following statement on Facebook today regarding the global Ice ... specifically for ALS research: , “Who would have thought ... raise all this awareness and funding toward ALS research! ... of the entire ALS community, would like to express ...
(Date:8/26/2014)... 26, 2014  ViveBio, LLC a leading provider ... and transportation, announced today that it has signed ... (LPS) of Knoxville, Tennessee ... the United States . ViveST is ... temperature dried biological specimen transport systems.  The technology ...
(Date:8/26/2014)... (PRWEB) August 26, 2014 Genedata, ... drug discovery and life science research, today announced ... will be held in Asia, Europe, and ... global pharmaceutical companies and leading research organizations will ... best practices, case studies, and upcoming challenges in ...
Breaking Biology Technology:Students at Cleveland's University School Conduct Biomedical Research at Case Western Reserve University’s School of Medicine 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 3ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 4ViveBio and Laboratory Procurement Services Sign Agreement for Distribution of the ViveST Line of Products 2Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings 2Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings 3
... 21 CV Therapeutics,Inc. (Nasdaq: CVTX ) announced ... been accepted for presentation at the American,College of Cardiology ... Chicago, IL on March 29 - April 1, 2008., ... Activity in Isolated Rat Left Atrial,Appendage; Poster; Sunday, March ...
... Biopharmaceuticals,Inc. (Nasdaq: KERX ) will hold a conference ... to discuss the fourth quarter and year-end 2007,financial results ... Chief Executive Officer of the Company, will host the ... in a press release to be,issued prior to the ...
... PDL BioPharma Have Entered into an Agreement Under, Which Genmab ... ... Minnesota, USA, COPENHAGEN, Denmark and REDWOOD CITY, California, February ... PDLI ) announced today that they have entered into an ...
Cached Biology Technology:CV Therapeutics Announces Presentations at the American College of Cardiology 57th Annual Scientific Session 2CV Therapeutics Announces Presentations at the American College of Cardiology 57th Annual Scientific Session 3Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST 2Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 2Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 4Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 5
(Date:8/26/2014)... the University of Liverpool has recommended investing in dog owner ... and problems such as obesity in both people and their ... 1990, the researchers found that access to dog-friendly walking environments ... people to get out and take more exercise with their ... don,t take their dogs for a walk. In the UK, ...
(Date:8/25/2014)... biofuels industry: "You can make anything from lignin ... pave the way to challenging that adage. The ... Laboratory (NREL) demonstrates a concept that provides opportunities ... variety of renewable fuels, chemicals, and materials for ... Through Integrated Biological Funneling and Chemical Catalysis " ...
(Date:8/25/2014)... of proteins that promotes virus entry into cells also ... and other viruses, University of Missouri researchers have found. ... insights into our understanding of not only HIV infection, ... Shan-Lu Liu, M.D., Ph.D., associate professor in the MU ... , The study was recently published in the ...
Breaking Biology News(10 mins):Education and dog-friendly neighbourhoods could tackle obesity 2New process helps overcome obstacles to produce renewable fuels and chemicals 2MU researchers discover protein's ability to inhibit HIV release 2MU researchers discover protein's ability to inhibit HIV release 3
... Researchers are still fascinated by the idea of the ... them into cells with the capacity to differentiate into ... are still striving to understand how it happens. ... (CNIO), headed by researcher Ralph P. Schneider, from the ...
... A new study finds that utilities aren,t rewarded for ... to make energy efficiency as attractive as renewables. ... Environmental Law , examines key differences between energy ... assistant professor at Oregon State University, outlines ways to ...
... a private company focused on the development of targeted ... has entered into a license agreement with the Spanish ... rights to develop and commercialise several novel kinase inhibitors ... CNIO,s considerable expertise in drug discovery and comprise a ...
Cached Biology News:CNIO researchers identify a new gene that is essential for nuclear reprogramming 2Study finds disincentives to energy efficiency can be fixed 2